Eli Lilly Reports Dosing of its First Patient with Tirzepatide in P-III SURPASS-CVOT Study for Cardiovascular Outcomes

 Eli Lilly Reports Dosing of its First Patient with Tirzepatide in P-III SURPASS-CVOT Study for Cardiovascular Outcomes

Lilly and Junshi Collaborate to Co-Develop Antibody Therapies for the Treatment of COVID-19

Shots:

  • The P-III SURPASS-CVOT study involves assessing non-inferiority and superiority of tirzepatide vs Trulicity (dulaglutide, 15mg) in 12,500 patients with T2D and atherosclerotic cardiovascular disease from 30 countries. The company expects for the completion of trial in four years
  • The 1EPs will measure time to first occurrence of MACE-3, the composite endpoint of CV death, myocardial infarction, or stroke while the 2EPs is time to all-cause mortality and time to occurrence of each component of the primary endpoint
  • Trulicity (dulaglutide) is an injectable prescribed medicine for T2D patients used to improve blood sugar (glucose) and used to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in people who have heart disease or multiple cardiovascular risk factors

Click here to read full press release/ article | Ref: PRNewswire | Image:Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post